Helius stock up 38% on launch of patient program for neuromodulation stimulator therapy
seekingalpha.com
finance
2022-06-01 15:36:44

gorodenkoff/iStock via Getty Images Helius Medical Technologies (NASDAQ:HSDT) stock rose ~38% on June 1 after the company said it launched its Patient Therapy Access Program (PTAP). Helius said PTAP will provide qualifying patients access to on-label Portable Neuromodulation Stimulator (PoNS) therapy at a significantly reduced price. PoNS is indicated in the U.S. for use as a short-term treatment of walking issue in adults with mild-to-moderate symptoms from multiple sclerosis (MS) and is available by prescription only, Helius said in a June 1 press release.
